Legacy Healthcare Welcomes U.S. Congressional Legislation Proposing 12-Year Market Exclusivity for US FDA Newly Approved Botanical Drugs

RegulatoryPositive

AI Analysis

Summary

Legacy Healthcare welcomes proposed U.S. Congressional legislation introduced on August 27, 2026, that would grant 12-year post-approval market exclusivity for newly approved FDA-regulated botanical drugs to encourage innovation investment.

Outcome Details

Congressional legislation proposed to provide 12-year post-approval market exclusivity for FDA-approved botanical drugs

Importance:4/10

Sentiment:

0.60

regulatorybotanical drugsmarket exclusivityFDAlegislationcongressional

Related Companies

$HR $DMIIR

Read the original article

Published by PR Newswire Pharma on September 3, 2026 12:15 PM

Read Original